Aclaris Therapeutics vs Camp4 Therapeutics
ACRS and CAMP side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ACRS and CAMP compare
Aclaris Therapeutics is the larger company, worth 2.3 times as much as Camp4 Therapeutics ($589M against $257M).
Camp4 Therapeutics grew revenue faster over the last twelve months (39.9% versus −59.3% for Aclaris Therapeutics).
Aclaris Therapeutics keeps more of each dollar of sales as profit, with a net margin of −1244% compared with −2276% at Camp4 Therapeutics.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ACRS | CAMP |
|---|---|---|
| Size and price | ||
| Market cap | $589M | $257M |
| Share price | $4.00 | $4.09 |
| Change, 1 year | 73.9% | −0.97% |
| Change, 5 years | −71.0% | −98.2% |
| Beta (5Y) | 1.14 | 2.72 |
| Employees | 73 | 48 |
| StockData Score | ||
| Total score | 6 | 6 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 1 (better) | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 92.0× | 48.2× (better) |
| P/B | 3.5× | 2.4× (better) |
| FCF yield | −12.8% | −10.3% (better) |
| Fair value | – | $2.51 |
| Margin of safety | – | −63.0% |
| Growth | ||
| Revenue growth (TTM) | −59.3% | 39.9% (better) |
| Revenue growth, 5Y average | 3.8% | – |
| Profitability | ||
| Gross margin | 79.2% | – |
| Operating margin | −1414% | −1001% (better) |
| Net margin | −1244% (better) | −2276% |
| FCF margin | −1177% | −496% (better) |
| Return on equity | −55.5% (better) | −146% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 5.09 | 6.42 (better) |
| Altman Z-score | −0.30 | 1.52 (better) |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 82.3% | 66.5% |
| Held by insiders | 13.3% | 21.7% |
| Insider net buying, 12 months | −$1.4M (better) | −$2.4M |
| Short interest, % of float | 9.1% | 6.6% |
Go deeper
- ACRS stock overview
- ACRS income statement
- ACRS valuation and score
- CAMP stock overview
- CAMP income statement
- CAMP valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.